Zimmer Biomet filed a 510(k) submission with the FDA on November 18, 2026, for a fully autonomous version of its Monogram knee replacement robot, CEO Ivan Tornos confirmed at an investor event. The filing starts a 90-day review clock and, if cleared, would bring the product to market in 2027 — a year earlier than the company's original 2028 target.
Monogram came to Zimmer Biomet through its 2025 acquisition of Monogram Technologies for $177 million. The current semi-autonomous version requires a surgeon to guide the robotic arm during total knee replacement. The new filing covers a hands-free mode: a surgeon activates the system with a foot pedal, and the robot independently performs bone preparation and landmark identification using CT-based imaging. A clinical trial supporting the submission reported zero safety events, along with faster bone preparation, improved landmarking accuracy and fewer instrument trays needed per case, according to MedTech Dive.
Why Autonomy Changes the Economics of Knee Surgery
Robotic knee replacement has so far meant a surgeon-driven arm that assists cutting but still demands constant manual input. An autonomous bone-prep step shifts the surgeon's role toward supervision, which could shorten operating room time and reduce the physical strain surgeons report from guiding heavy robotic arms through repetitive procedures. For hospitals running high volumes of knee replacements, even small per-case time savings compound into real throughput gains.
Tornos called the technology "new-to-the-world" and said he expects some back-and-forth with regulators given the novelty of the autonomous claim. That caution is notable: the FDA has historically cleared robotic surgery systems as surgeon-assist tools, and a hands-free bone-cutting step for a load-bearing joint raises different liability and training questions than existing clearances for Zimmer's own Rosa system or Johnson & Johnson's Ottava platform.
A Crowded Field Getting More Autonomous
Zimmer's Rosa, Stryker's Mako and Smith+Nephew's Cori all currently rely on surgeon-guided robotic arms for knee and hip procedures. Stryker has said roughly two in three robotic knee replacements performed in the US now run on its Mako platform, underscoring how much ground Zimmer and others have to make up. Monogram's pitch is to leapfrog that generation by removing the surgeon's hand from the cutting step entirely, rather than competing on arm precision alone.
The push toward autonomy mirrors a broader industry pattern: surgical robotics vendors are layering AI-driven automation onto platforms originally sold as manual-assist tools, hoping to capture efficiency gains hospitals can measure in minutes and instrument costs. If the FDA clears Monogram's autonomous mode in 2027 as planned, it would be among the first fully hands-free orthopedic robots on the US market, giving Zimmer Biomet a distinct claim against Stryker and J&J heading into the next wave of knee-replacement volume growth.